Yibin Feng
The University of Hong Kong, China
Title: Traditional Materials To Modern Drug: How Chinese Medicines Contribute To New Drug Discovery
Biography
Biography: Yibin Feng
Abstract
Facing complicated diseases and unmet medical needs, drug discovery and development from Chinese medicines should have new strategy. There are about 25% modern drug inspired from traditional medicine including Chinese Medicine. The way of drug discovery and development in past 100 years is from natural rescouses to chemical sythsesis, but no matter natural compounds or sythsized compounds for drug discovery and development are more and more difficult. Not only experinced natural materials, but also wisdom and knowlege in traditional medicine may help form new strategy to discover new drug. It is known that 25% modern drugs were inspired from traditional medicine. It has been intensively studied a lot about natural resourse in terms of chmical and pharmacological profiles. So far, over 10000 single compounds were isolated from Chinese medicines (Chinese medicinal plants, animal parts and minerals) among which some have been identified as new drugs such as ephedrine, artnisinin and asenic trioxide etc., while others are promissing drug candidates suggesting Chinese medicines are still an important resource for new drug discovery. It is more amazing if we watch composite formulae, they are over 100000 in total. Clinically, Chinese medicine mainly use composite formulae to treat varouse diseases, especially complicated diseases. Recently, both experimental and clinical studies showed Realgar-indigo naturalies, Qili Qaingxin cupsules and Compound Danshen Dripping Pills are promising formulae for treatment of acute promyelocytic leukemia, chronic heart failure and coronary heart disease. Actually, Western medicine also offen use combination therapy for diseases treatment in clinical setting, such as cancer, hypertension and AIDS etc.. To this goal, we developed a comprehensive, dynamic and specific strategy for drug discovery for cancer and metabolic diseases as one attempt. This presentation will talk about drug discovery from single compounds to multiple components as drug candidates in Chinese medicine by recent developed technologies. The research was financially supported by grants from the RGC GRF, Hong Kong SAR of China (Project codes: 764708, 766211, 17152116), ITF grant (Project code: 260900263), HA Chinese Medicine grant (Project code: 200006345), Donations for Wong’s molecular cancer research in Chinese medicines (Project code: 200006276), the Gaia Family Trust (Project code:200007008) and Vita Green Health Products Co., Ltd. (Project cord: 200007477), and Hong Kong Government Matching funding (Project codes: 207040314, 207060411) as well as industry contract grants (Project codes: 260007482, 260007830).